Computation as the mechanistic bridge between precision medicine and systems therapeutics

Clinical Pharmacology and Therapeutics

Volumn 93, Issue 1, 2013, Pages 117-128

  Hansen, J ^a   Iyengar, R ^a  

^a Systems Biology Center New York   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARACHIDONIC ACID; BRCA1 PROTEIN; BRCA2 PROTEIN; CIMETIDINE; CISPLATIN; CLAUDIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HEAT SHOCK PROTEIN 90; IMATINIB; METHOTREXATE; MICRORNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MRE11 PROTEIN; PROPRANOLOL; RAF PROTEIN;

ANALYTIC METHOD; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; COPY NUMBER VARIATION; DISEASE COURSE; DNA METHYLATION; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; EPIGENETICS; GENE EXPRESSION; GENE MUTATION; GENETIC VARIABILITY; GENOMICS; HUMAN; HYPERTENSION; KNOWLEDGE; MICROARRAY ANALYSIS; MOLECULAR BIOLOGY; PATHOPHYSIOLOGY; PRECISION MEDICINE; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; PROTEOMICS; QUANTITATIVE TRAIT LOCUS; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMS BIOLOGY; TREATMENT OUTCOME;

COMPUTATIONAL BIOLOGY; GENOMICS; HUMANS; INDIVIDUALIZED MEDICINE; INFORMATION SERVICES; SYSTEMS BIOLOGY;

EID: 84871288039     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2012.199     Document Type: Article

References (54)

1. Walker, M.J. The major impacts of James Black's drug discoveries on medicine and pharmacology. Trends Pharmacol. Sci. 32, 183-188 (2011).
2. Tarabuso, A.L. Fabry disease. Skinmed. 9, 173-177 (2011).
3. Committee on a Framework for Development of a New Taxonomy of Disease. Toward Precision Medicine: Cuilding a Knowledge Network for Biomedical Research and a New Taxonomy of Disease (National Academy of Sciences, Washington, DC, 2011).
4. Koboldt, D.C. et al. Comprehensive molecular portraits of human breast tumours. Nature 490 (7418), 61-70 (2012).
5. Yildirim, M.A., Goh, K.I., Cusick, M.E., Barabási, A.L. & Vidal, M. Drug-target network. Nat. Biotechnol. 25, 1119-1126 (2007).
6. Paul, S.M. et al. How to improve R&D productivity: The pharmaceutical industry's grand challenge. Nat. Rev. Drug Discov. 9, 203-214 (2010).
7. Zhao, S. & Iyengar, R. Systems pharmacology: Network analysis to identify multiscale mechanisms of drug action. Annu. Rev. Pharmacol. Toxicol. 52, 505-521 (2012).
8. Hong, C.P., Park, J. & Roh, T.Y. Epigenetic regulation in cell reprogramming revealed by genome-wide analysis. Epigenomics 3, 73-81 (2011).
9. Namjou, B., Kilpatrick, J. & Harley, J.B. Genetics of clinical expression in SLE. Autoimmunity 40, 602-612 (2007).
10. Samani, N.J. et al.; WTCCC and the Cardiogenics Consortium. Genomewide association analysis of coronary artery disease. N. Engl. J. Med. 357, 443-453 (2007).
11. The Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 487 (7407), 330-337 (2012).
12. Weijers, R.N. Risk loci for type 2 diabetes - quo vadis? Clin. Chem. Lab. Med. 47, 383-386 (2009).
13. Grant, S.F. & Hakonarson, H. Microarray technology and applications in the arena of genome-wide association. Clin. Chem. 54, 1116-1124 (2008).
14. Malone, J.H. & Oliver, B. Microarrays, deep sequencing and the true measure of the transcriptome. BMC Biol. 9, 34 (2011).
15. Yandell, M. & Ence, D. A beginner's guide to eukaryotic genome annotation. Nat. Rev. Genet. 13, 329-342 (2012).
16. Hartwell, L.H., Hopfield, J.J., Leibler, S. & Murray, A.W. From molecular to modular cell biology. Nature 402, C47-C52 (1999).
17. Han, J.D. et al. Evidence for dynamically organized modularity in the yeast protein-protein interaction network. Nature 430, 88-93 (2004).
18. Taylor, I.W. et al. Dynamic modularity in protein interaction networks predicts breast cancer outcome. Nat. Biotechnol. 27, 199-204 (2009).
19. van de Vijver, M.J. et al. A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med. 347, 1999-2009 (2002).
20. Barabási, A.L., Gulbahce, N. & Loscalzo, J. Network medicine: A network-based approach to human disease. Nat. Rev. Genet. 12, 56-68 (2011).
21. Goh, K.I., Cusick, M.E., Valle, D., Childs, B., Vidal, M. & Barabási, A.L. The human disease network. Proc. Natl. Acad. Sci. USA 104, 8685-8690 (2007).
22. Chen, J.Y., Shen, C. & Sivachenko, A.Y. Mining Alzheimer disease relevant proteins from integrated protein interactome data. Pac. Symp. Biocomput., 367-378 (2006).
23. Alvarez, A.R., Godoy, J.A., Mullendorff, K., Olivares, G.H., Bronfman, M. & Inestrosa, N.C. Wnt-3a overcomes beta-amyloid toxicity in rat hippocampal neurons. Exp. Cell Res. 297, 186-196 (2004).
24. Fuentealba, R.A., Farias, G., Scheu, J., Bronfman, M., Marzolo, M.P. & Inestrosa, N.C. Signal transduction during amyloid-beta-peptide neurotoxicity: Role in Alzheimer disease. Brain Res. Brain Res. Rev. 47, 275-289 (2004).
25. Berger, S.I., Ma'ayan, A. & Iyengar, R. Systems pharmacology of arrhythmias. Sci. Signal. 3, ra30 (2010).
26. Druker, B.J. et al.; IRIS Investigators. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N. Engl. J. Med. 355, 2408-2417 (2006).
27. de Ruijter, T.C., Veeck, J., de Hoon, J.P., van Engeland, M. & Tjan-Heijnen, V.C. Characteristics of triple-negative breast cancer. J. Cancer Res. Clin. Oncol. 137, 183-192 (2011).
28. Duncan, J.S., Whittle, M.C., Nakamura, K., Abell, A.N., Midland, A.A., Zawistowski, J.S. et al. Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer. Cell 149, 307-321 (2012).
29. Straussman, R. et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 487, 500-504 (2012).
30. Wilson, T.R. et al. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature 487, 505-509 (2012).
31. Komurov, K., Dursun, S., Erdin, S. & Ram, P.T. NetWalker: A contextual network analysis tool for functional genomics. BMC Genomics 13, 282 (2012).
32. Hotamisligil, G.S. Endoplasmic reticulum stress and the inflammatory basis of metabolic disease. Cell 140, 900-917 (2010).
33. Lamb, J. et al. The Connectivity Map: Using gene-expression signatures to connect small molecules, genes, and disease. Science 313, 1929-1935 (2006).
34. Schadt, E.E. et al. An integrative genomics approach to infer causal associations between gene expression and disease. Nat. Genet. 37, 710-717 (2005).
35. Chen, Y. et al. Variations in DNA elucidate molecular networks that cause disease. Nature 452, 429-435 (2008).
36. Emilsson, V. et al. Genetics of gene expression and its effect on disease. Nature 452, 423-428 (2008).
37. Lum, P.Y. et al. Elucidating the murine brain transcriptional network in a segregating mouse population to identify core functional modules for obesity and diabetes. J. Neurochem. 97 (suppl. 1), 50-62 (2006).
38. Lumeng, C.N., Bodzin, J.L. & Saltiel, A.R. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J. Clin. Invest. 117, 175-184 (2007).
39. Lumeng, C.N., Deyoung, S.M., Bodzin, J.L. & Saltiel, A.R. Increased inflammatory properties of adipose tissue macrophages recruited during diet-induced obesity. Diabetes 56, 16-23 (2007).
40. Yap, T.A. & Workman, P. Exploiting the cancer genome: Strategies for the discovery and clinical development of targeted molecular therapeutics. Annu. Rev. Pharmacol. Toxicol. 52, 549-573 (2012).
41. Arteaga, C.L., Sliwkowski, M.X., Osborne, C.K., Perez, E.A., Puglisi, F. & Gianni, L. Treatment of HER2-positive breast cancer: Current status and future perspectives. Nat. Rev. Clin. Oncol. 9, 16-32 (2012).
42. Modi, S. et al. Combination of trastuzumab and tanespimycin (17-AAG, KOS- 953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: A phase I dose-escalation study. J. Clin. Oncol. 25, 5410-5417 (2007).
43. Fong, P.C. et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N. Engl. J. Med. 361, 123-134 (2009).
44. Barretina, J. et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483, 603-607 (2012).
45. Garnett, M.J. et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 483, 570-575 (2012).
46. Heiser, L.M. et al. Subtype and pathway specific responses to anticancer compounds in breast cancer. Proc. Natl. Acad. Sci. USA 109, 2724-2729 (2012).
47. Carey, L.A. et al. The triple negative paradox: Primary tumor chemosensitivity of breast cancer subtypes. Clin. Cancer Res. 13, 2329-2334 (2007).
48. Silver, D.P. et al. Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. J. Clin. Oncol. 28, 1145-1153 (2010).
49. Vaske, C.J. et al. Inference of patient-specific pathway activities from multidimensional cancer genomics data using PARADIGM. Bioinformatics 26, i237-i245 (2010).
50. Pick, E. et al. High HSP90 expression is associated with decreased survival in breast cancer. Cancer Res. 67, 2932-2937 (2007).
51. Panetta, J.C., Sparreboom, A., Pui, C.H., Relling, M.V. & Evans, W.E. Modeling mechanisms of in vivo variability in methotrexate accumulation and folate pathway inhibition in acute lymphoblastic leukemia cells. PLoS Comput. Biol. 6, e1001019 (2010).
52. Hector, S. et al. Clinical application of a systems model of apoptosis execution for the prediction of colorectal cancer therapy responses and personalisation of therapy. Gut 61, 725-733 (2012).
53. Yang, K., Bai, H., Ouyang, Q., Lai, L. & Tang, C. Finding multiple target optimal intervention in disease-related molecular network. Mol. Syst. Biol. 4, 228 (2008).
54. Iyengar, R., Zhao, S., Chung, S.W., Mager, D.E. & Gallo, J.M. Merging systems biology with pharmacodynamics. Sci. Transl. Med. 4, 126ps7 (2012).